"The voice for cancer physicians and their patients in Massachusetts."
The U.S. Food and Drug Administration approved crizanlizumab-tmca (Adakveo; Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. Read full press release.
Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451
Waltham, MA. 02451